Igloo Launches ‘The Cooler Brand’ Campaign Inspiring Enjoyment for All
12.6.2025 18:00:00 CEST | Business Wire | Press Release
Today,Igloo premieres its ‘The Cooler Brand’ global campaign, a playful calling card celebrating the diverse tapestry of cultures that define the colorful world of Igloo. Featuring an eclectic cast of fascinating characters and enticing scenes, Igloo’s new brand campaign encourages everyone — of any age from anywhere (and everyone in between) — to have fun together. Enjoy the full experience at TheCoolerBrand.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612471092/en/
Igloo Launches ‘The Cooler Brand’ Campaign Inspiring Enjoyment for All
“As ‘The Cooler Brand’, Igloo is connecting with a broader audience, inviting individuals from all walks of life to enjoy our products, rather than focusing solely on elite outdoor enthusiasts, although we love them too,” said Josh Militello, President of Dometic Mobile Cooling and Igloo Coolers. “Adopting a lighthearted and stylized approach sets Igloo apart in the market, highlighting our commitment to accessibility, community and creativity while prioritizing the spirit of fun in our messaging. This strategy not only fosters a welcoming atmosphere but also resonates with Igloo’s very diverse audience.”
Since its inception in 1947, Igloo has evolved into a lifestyle brand synonymous with dependability and innovation in cooling. For Igloo, being “The Cooler Brand” means knowing exactly what the brand stands for, showing up authentically and striving to create products that provide joy to everyone, no matter who they are or where they are from.
Igloo’s campaign bursts to life thanks to a lineup of world-class creatives. Among them is the award-winning photographer Ryan Schude who is renowned for his energetic, wide images that capture multiple characters in a single frame. His work on this campaign invites viewers to explore the adventurous world of Igloo, filled with vibrant and entertaining details. Additionally, eagle-eye music fans will notice band members from the Black Lips prominently featured in the campaign photography.
'The Cooler Brand' campaign highlights the practicality, durability, versatility and stylish design of Igloo products. As the centerpiece of enjoyment, Igloo products allow people to create memorable moments together, whether they are crouching over, sitting on, packing in or opening up their favorite cooler. Igloo is and always has been the original ‘Cooler Brand’.
Shop Igloo’s versatile product assortment at leading retailers worldwide and at IglooCoolers.com in the USA.
To keep up with all things Igloo:
Instagram
Facebook
Twitter
YouTube
About Igloo:
Born from a modest metalworking shop back in 1947, Igloo has been instrumental in redefining how we live, work and play. What began with bringing clean water to the worksite quickly moved into super-functional, best-in-class ice chests. Igloo products made the family outdoor recreation movement of the 20th century possible. Suddenly, taking your kids camping on the weekend became easy and cross-country road trips became a summer vacation staple.
As we approach our next century, Igloo is 1,200 employees strong. We are proud to call—a 1.8-million-square-foot, three-building facility in—Katy, Texas home. With more than 500 products sold at thousands of retailers around the globe, we can confidently call ourselves the number one cooler manufacturer in the world.
And through it all we haven’t lost sight of our original goal—to create products that enable the pursuit of happiness (however you define it). That’s why we’re still working hard every day to innovate, create and make it easier for you to get out, work hard and play even harder.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612471092/en/
Contacts
Igloo Press Contacts:
Master Plan Communications, Inc.
Debs Loomis
714.310.9651
deborah@masterplancommunications.com
OR
Emme Rothberg
214.642.2928
emme@masterplancommunications.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom